Small Molecules

17 Dec 2019 Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients
17 Dec 2019 Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
17 Dec 2019 ARMGO® Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
17 Dec 2019 Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
17 Dec 2019 XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
16 Dec 2019 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
16 Dec 2019 BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
16 Dec 2019 BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide
16 Dec 2019 ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist at 2019 San Antonio Breast Cancer Symposium
16 Dec 2019 Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
16 Dec 2019 Gilead Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis (F3) and Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
16 Dec 2019 Futility Analysis Performed of the Phase II Combination Study with Birinapant and Keytruda® in Colorectal Cancer Patients
16 Dec 2019 Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
15 Dec 2019 Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
13 Dec 2019 Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates
13 Dec 2019 Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
13 Dec 2019 Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
13 Dec 2019 Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
13 Dec 2019 Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting
13 Dec 2019 Kaleido Biosciences to Advance KB174 for Hepatic Encephalopathy Based on Positive Top-Line Results from a Clinical Study in Patients with Cirrhosis
13 Dec 2019 Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCS
13 Dec 2019 FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
12 Dec 2019 iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA
12 Dec 2019 CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
11 Dec 2019 Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes Ineligible for Approved CFTR Modulators

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up